AmbioPharm
North Augusta, SC
Program data pending ClinicalTrials.gov matching
57.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (2)
○ EMA GMP
○ MHRA GMP
Quick Facts: AmbioPharm
- Signal Score
- 57.5/100
- Quality Compliance
- Assessment pending
- Headquarters
- North Augusta, SC
- Modalities
- Peptide API, Peptide Vaccines, GMP Peptide Synthesis
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About AmbioPharm
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesPeptide API, Peptide Vaccines, GMP Peptide Synthesis
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
55.0
Manufacturing site information being gathered
Modalities: Peptide API, Peptide Vaccines, GMP Peptide Synthesis
Capacity assessment: 55.0/100
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press2 articles
Manufacturing site information being gathered
Modalities: Peptide API, Peptide Vaccines, GMP Peptide Synthesis
Capacity assessment: 55.0/100
Recent News 2 articles
CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity - PR Newswire
GLP-1 manufacturer CordenPharma strikes deal for peptide CDMO, lining up new production sites in US and China - Fierce Pharma
Frequently Asked Questions About AmbioPharm
What is AmbioPharm's CDMO Signal Score?
AmbioPharm has a Signal Score of 58/100, based on quality, operations, financial stability, and capacity data.
Evaluating AmbioPharm for a manufacturing program?
Use the free AI matchmaker to compare AmbioPharm against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.